Research & Development News Channel

Experimental COVID-19 vaccine protects upper and lower airways in nonhuman primates

Two doses of an experimental vaccine to prevent coronavirus disease 2019 (COVID-19) induced robust immune responses and rapidly controlled the coronavirus in the upper and lower airways of rhesus macaques exposed to SARS-CoV-2, report scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. SARS-CoV-2 is the virus that causes COVID-19.

Another mRNA-based vaccine candidate protects animals against SARS-CoV-2

An experimental messenger RNA (mRNA)-based vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicits protective immune responses in mice and non-human primates, researchers report on July 23rd in the journal Cell. Two injections of the vaccine were sufficient to induce robust immunity, completely preventing SARS-CoV-2 infection in mice.

Neutralizing antibodies isolated from COVID-19 patients may suppress virus

Researchers at Columbia University Irving Medical Center have isolated antibodies from several COVID-19 patients that, to date, are among the most potent in neutralizing the SARS-CoV-2 virus.

These antibodies could be produced in large quantities by pharmaceutical companies to treat patients, especially early in the course of infection, and to prevent infection, particularly in the elderly.

Scientists uncover SARS-CoV-2-specific T cell immunity in recovered COVID-19 and SARS patients

The study by scientists from Duke-NUS Medical School, in close collaboration with the National University of Singapore (NUS) Yong Loo Lin School of Medicine, Singapore General Hospital (SGH) and National Centre for Infectious Diseases (NCID) was published in Nature.

Common FDA-approved drug may effectively neutralize virus that causes COVID-19

A common drug, already approved by the Food and Drug Administration (FDA), may also be a powerful tool in fighting COVID-19, according to research published this week in Antiviral Research.

SARS-CoV-2, the virus that causes COVID-19, uses a surface spike protein to latch onto human cells and initiate infection.

Drug linked to 45% lower risk of dying among COVID-19 patients on ventilators

Critically ill COVID-19 patients who received a single dose of a drug that calms an overreacting immune system were 45% less likely to die overall, and more likely to be out of the hospital or off a ventilator one month after treatment, compared with those who didn't receive the drug, according to a new study by a team from the University of Michigan.

Researchers call for worldwide biosurveillance network to protect from diseases

The emergence of COVID-19 is a powerful reminder of how unchecked wildlife trade can lead to the spillover spread of viruses between wildlife and humans. Understanding that wholesale bans on trade can affect community livelihoods and food security, the pandemic underscores the need for widespread pathogen screening and monitoring to better understand, predict and contain outbreaks in wildlife and humans.

Research & Development News

Experimental COVID-19 vaccine protects upper and lower airways in nonhuman primates

Another mRNA-based vaccine candidate protects animals against SARS-CoV-2

Neutralizing antibodies isolated from COVID-19 patients may suppress virus

Scientists uncover SARS-CoV-2-specific T cell immunity in recovered COVID-19 and SARS patients

Common FDA-approved drug may effectively neutralize virus that causes COVID-19

Drug linked to 45% lower risk of dying among COVID-19 patients on ventilators

Researchers call for worldwide biosurveillance network to protect from diseases

More Pharma News ...

Business & Industry

Research & Development

Conferences & Events

Regulatory Affairs